Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0417)
Name |
2-pyridylhydrazone dithiocarbamate s-acetic acid
|
||||
---|---|---|---|---|---|
Drug Type |
Small molecule
|
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Apoptosis | hsa04210 | |||
Cell Process | Cell ferroptosis | |||
Cell autophagy | ||||
Cell apoptosis | ||||
In Vitro Model | Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 |
Response regulation | 2-pyridylhydrazone dithiocarbamate s-acetic acid (PdtaA) induced both apoptosis and cell cycle arrest. Notably, PdtaA also induced ferroptosis via downregulation of GPx4 and xCT in liver cancer cells. Autophagy inhibitor 3-methyladenin or genetic knockdown of NCOA4 was employed to inhibit ferritinophagy, which significantly neutralized the action of PdtaA in both apoptosis and ferroptosis. | |||
Nuclear receptor coactivator 4 (NCOA4)
In total 2 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Apoptosis | hsa04210 | |||
Cell Process | Cell ferroptosis | |||
Cell autophagy | ||||
Cell apoptosis | ||||
In Vitro Model | Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 |
Response regulation | 2-pyridylhydrazone dithiocarbamate s-acetic acid (PdtaA) induced both apoptosis and cell cycle arrest. Notably, PdtaA also induced ferroptosis via downregulation of GPx4 and xCT in liver cancer cells. Autophagy inhibitor 3-methyladenin or genetic knockdown of NCOA4 was employed to inhibit ferritinophagy, which significantly neutralized the action of PdtaA in both apoptosis and ferroptosis. | |||
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target | [2] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell adhesion molecules | hsa04514 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model | Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 |
Response regulation | Knockdown of NCOA4 significantly attenuated the regulatory effect of 2-pyridylhydrazone dithiocarbamate s-acetic acid (PdtaA) on related proteins which highlighted that the strength of ferritinophagic flux (NCOA4/ferritin) was a driving force in determination of the status of EMT and ferroptosis. PdtaA treatment resulted in ferritinophagy that triggered ROS production in liver cancer cells. | |||
References